Clinical inertia in the management of patients with type 2 diabetes: How to solve it?;Inertie clinique dans la prise en charge du patient diabètique de type 2: Quelles solutions proposer?

Revue Medicale de Liege

Volumn 65, Issue 5-6, 2010, Pages 318-325

  Philips, J C ^a,b   Scheen, A J ^a,b  

^a UNIVERSITY OF LIÈGE   (Belgium)

^b UNIVERSITY OF LIÈGE   (Belgium)

Author keywords

Clinical inertia; Combined therapy; Shared care; Treat to target; Treatment failure; Type 2 diabetes

Indexed keywords

EXENDIN 4; LIRAGLUTIDE; METFORMIN; ONLYZA; ORAL ANTIDIABETIC AGENT; PIOGLITAZONE; REPAGLINIDE; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; UNCLASSIFIED DRUG; VILDAGLIPTIN;

DRUG EFFICACY; HEALTH PROMOTION; HUMAN; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT CARE; REVIEW; TREATMENT FAILURE; TREATMENT RESPONSE;

ATTITUDE OF HEALTH PERSONNEL; COMBINED MODALITY THERAPY; DIABETES MELLITUS, TYPE 2; GUIDELINE ADHERENCE; HUMANS; PRACTICE GUIDELINES AS TOPIC;

EID: 77954102211     PISSN: 00353663     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (40)

1. Numéro special. - Le diabète sucré dans tous ses états. Rev Med Liège, 2005, 60, 269-631.
2. Scheen AJ, Paquot N, Lefèbvre PJ. - United Kingdom Prospective Diabetes Study : 10 ans plus tard .... Rev Med Liège, 2008, 63, 624-629.
3. Nathan DM, Buse JB, Davidson MB, et al. - Medical management of hyperglycaemia in type 2 diabetes : a consensus algorithm for the initiation and adjustment of therapy: a consensus statement from the American Diabetes Association and the European Association for the Study of Diabetes. Diabetologia, 2009, 52, 17-30.
4. Blonde L. - Current antihyperglycemic treatment guidelines and algorithms for patients with type 2 diabetes mellitus. Am J Med, 2010, 123, S12-18.
5. Radermecker R, Philips JC, Jandrain B, et al. - Contrôle glycémique et morbi- mortalité cardio-vasculaire chez le patient diabétique de type 2. Résultats des études ACCORD, ADVANCE et VA-Diabetes. Rev Med Liège, 63, 511-518.
6. Scheen AJ, Radermecker RP, Philips JC, et al. - Le traitement du diabète de type 2 : entre insulinosensibilisateurs et insulinosécrétagogues. Rev Med Liège, 2007, 62, (numéro spécial), 40-46.
7. Scheen AJ, Paquot N.- Quelle nouvelle donne pour soigner les patients diabétiques de type 2 ? Médecine des Maladies Métaboliques, 2009, 3, 141-146.
8. American Diabetes Association. - Standard of medical care in diabetes - 2010. Diabetes Care, 2010, 33 (Suppl 1), S11-S61.
9. Scheen AJ, Lefèbvre PJ, Kulbertus H. - Prévention cardio- vasculaire : la "polypill", une solution pour vaincre l'inertie clinique et le manqué d'observance ? Rev Med Liège, 2010, 65, 267-272.
10. DeFronzo RA. - Banting Lecture. From the triumvirate to the ominous octet: a new paradigm for the treatment of type 2 diabetes mellitus. Diabetes, 2009, 58, 773-795.
11. Grant R, Cagliero E, Dubey A, et al. - Clinical inertia in the management of type 2 diabetes metablic risk factors. Diabet Med, 2004, 21, 150-155. (Pubitemid 38221814)
12. Brown J, Nichols G, Perry A. - The burden of treatment failure in type 2 diabetes. Diabetes Care, 2004, 97, 1535-1540. (Pubitemid 38857422)
13. Del Prato S, Felton A-M, Munro N, et al. - Improving glucose management: Ten steps to get more patients with type 2 diabetes to glycaemic goal. Int J Clin Pract, 2005, 59, 1345-1355.
14. Reach G. - Patient non-adherence and healthcare-provider inertia are clinical myopia. Diabetes Metab, 2008, 34, 382-385.
15. Grant R, Adams A, Trinacy C et al. - Relationship between patient medication adherence and subsequent clinical inertia in type 2 diabetes glycemic management. Diabetes Care, 2007, 30, 807-812.
16. Ziemer DC, Miller CD, Rhee MK, et al. - Clinical inertia contributes to poor diabetes control in a primary care setting. Diabetes Educ, 2005, 31, 564-571.
17. van Bruggen R, Gorter K, Stolk R, et al. - Clinical inertia in general practice : widespread and related to the outcome of diabetes care. Fam Pract, 2009, 26, 428-436.
18. Knecht LA, Gauthier SM, Castro JC, et al. - Diabetes care in the hospital : is there clinical inertia? J Hosp Med, 2006, 1, 151-160.
19. Shah B, Hux J, Laupacis A et al. - Clinical inertia in response to inadequate glycemic control : do specialists differ from primary care physicians ? Diabetes Care, 2005, 28, 600-606.
20. Scheen AJ. - Inertie dans la pratique médicale : causes, conséquences, solutions. Rev Med Liège, 2010, 65, 232-238.
21. Hsu W. - Consequences of delaying progression to optimal therapy in patients with type 2 diabetes not achieving glycemic goals. South Med J, 2009, 102, 67-76.
22. McEwen LN, Bilik D, Johnson SL, et al. - Predictors and impact of intensification of antihyperglycemic therapy in type 2 diabetes : translating research into action for diabetes (TRIAD). Diabetes Care, 2009, 32, 971-976.
23. Bolen SD, Bricker E, Samuels TA, et al. - Factors associated with intensification of oral diabetes medications in primary care provider-patient dyads : a cohort study. Diabetes Care, 2009, 32, 25-31.
24. Scheen AJ, Lefèbvre PJ. - Oral antidiabetic agents : a guide to selection. Drugs, 1998, 55, 225-236.
25. Paquot N. - Effets néfastes du défaut d'observance hygiéno-diététique et médicamenteuse chez le patient diabétique. Rev Med Liège, 2010, 65, 326-331.
26. Scheen AJ. - Pièges et conseils à propos de l'utilisation des antidiabétiques oraux conventionnels. Rev Med Liège, 2002, 57, 352-356.
27. Scheen AJ, Radermecker RP, Philips JC, Paquot N. - Les incrétinomimétiques et incrétinopotentiateurs dans le traitement du diabète de type 2. Rev Med Suisse, 2007, 3, 1884-1888.
28. Nicolucci A, Rossi MC. - Incretin-based therapies : a new potential treatment approach to overcome clinical inertia in type 2 diabetes. Acta Biomed, 2008, 79, 184-191.
29. Scheen AJ, Bruwier G, Schmitt H, au nom des membres de l'étude clinique DREAM. - Optimalisation de la prise en charge du patient diabétique de type 2 : résultats de l'étude «DREAM» en médecine générale. Rev Med Liège, 2003, 58, 139-146.
30. 2.- L'éducation thérapeutique: une solution pour vaincre l'inertie clinique et le défaut d'observance. Rev Med Liège, 2010, 65, 250-255.
31. 1c approach to control type 2 diabetes and prevent complications. Adv Ther, 2007, 24, 545-559.
32. Choleau C, Albisser A, Bar-Hen A et al. - A novel method for assessing insulin dose adjustements by patients with diabetes. J Diabetes Sci Technol, 2007, 1, 3-7.
33. De Block C, Paquot N, Daoudi N, et al. - Amélioration du contrôle glycémique et perte de poids sous exénatide chez des patients diabétiques de type 2 : résultats d'une étude rétrospective observationnelle multicentrique belge. Rev Med Liège, 64, 488-495.
34. Brunton S. - Implementing treatment guidelines for type 2 diabetes in primary care. Postgrad Med, 2009, 121, 125-138.
35. Goderis G, Borgermans L, Heyman J, et al. - Type 2 diabetes in primary care in Belgium : need for structured shared care. Exp Clin Endocrinol Diabetes, 2009, 117, 367-372.
36. Varroud-Vial M, Mechaly P, Joannidis S, et al. - Cooperation between general practitioners and diabetologists and clinical audit improve the management of type 2 diabetic patients. Diabetes Metab, 1999, 25, 55-63. (Pubitemid 29198226)
37. Scheen AJ.- Le trajet de soins dans le dédale de la pyramide du diabète de type 2. Revue de l' Association Belge du Diabète, 2009, 52, 8-13.
38. Nobels F, Debacker N, Scheen AJ, au nom du Conseil Scientifique d'IPQED. - Initiative pour la Promotion de la Qualité et Epidémiologie du Diabète sucré (IPQED). Rev Med Liège, 2005, 60, 624-627.
39. Campbell SM, Reeves D, Kontopantelis E, et al. - Effects of pay for performance on the quality of primary care in England. N Engl J Med, 2009, 361, 368-378. (Pubitemid 47057740)
40. Parchman M, Pugh J, Romero R, et al. - Competing demands or clinical inertia : the case of elevated glycosylated hemoglobin. Ann Fam Med, 2007, 5, 196-201. (Pubitemid 46889995)